Boehringer Ingelheim snags second client for its China CMO operation

Just days after announcing its inaugural deal, Boehringer Ingelheim's contract manufacturing operation in China has picked up a second client. The German drugmaker last week said it has an agreement to manufacture a monoclonal antibody candidate for Shanghai-based biotech ZAI Lab. This deal comes shortly after Boehringer said it has won its first client with a deal to manufacture immuno-oncology drugs for Beijing-based BeiGene, once it completes construction of a €35 million ($44.9 million) plant it is building in Shanghai. The facility, which the company is using to do contract manufacturing in China, is slated to be operational in Q1 2017 and to have about 65 employees. Release (PDF) | More

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.